The Veterans Bio-Medical Research Institute Inc.

The Veterans Bio-Medical Research Institute Inc., a tax-exempt nonprofit research organization headquartered in East Orange, New Jersey, conducts federally funded biomedical research focused on military service member and veteran health as a prime grant recipient (82% of recent awards) and as a sub-recipient on research initiatives led by academic medical institutions.

The institute's customer base concentrates on defense and health research agencies. The Defense Health Agency funds eight awards and the Department of Health and Human Services National Institutes of Health funds seven awards, together accounting for 86% of recent grant activity. The Department of Defense and the Department of the Army Medical Command each support four awards, with the NIH National Institute of Diabetes and Digestive and Kidney Diseases contributing one. All recent funding flows through federal research grant programs rather than procurement vehicles; the institute does not hold federal contracts or contract IDVs.

The institute's grant portfolio centers on military-deployment-related health conditions and translational biomedical research. Current prime-recipient work includes a $1.64 million project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective November 2026 through October 2030, investigating time-efficient high-resistance inspiratory muscle training to address exertional dyspnea in deployed veterans. A second DHA project grant, effective November 2024 through October 2027, carries $1,126,946 in funding for translational research on cardiovascular risk profiling of deployment-related respiratory disease. Prior work included a Gulf War-related neurodegeneration initiative funded by the DHA, ultimate completion June 2030. Place of performance is the institute's East Orange, New Jersey facility, with collaboration across academic and medical research partners including Nova Southeastern University, Baylor College of Medicine, University of Delaware, and Rutgers University. In its sub-recipient capacity, the institute participates in research consortia led by Rutgers The State University of New Jersey (medication prescribing in older adults with chronic kidney disease, awarded January 2026), the University of Delaware (iManage-SCI feasibility and efficacy testing for veterans, awarded September 2024), Baylor College of Medicine (preliminary work for human-subjects research and site preparation in support of clinical trials, awarded May 2024), and Nova Southeastern University (Gulf War Illness clinical trial recruitment and medical evaluation protocols, awarded October 2021).

Activity shows intermittent grant awards over a long timeline, with two awards in the current 2026 year and one award facing ultimate completion in the next twenty-four months. Combined potential value across all 28 awards totals $43 thousand, though combined dollars obligated reach $19.7 million, reflecting the institute's establishment as a funded research recipient with deep deployment-health research expertise.